Intrapericardial delivery of amiodarone and sotalol: Atrial transmural drug distribution and electrophysiological effects

Journal of Cardiovascular Pharmacology

Volumn 54, Issue 4, 2009, Pages 355-363

  Bolderman, Robert W ^a   Rob Hermans, J J ^b   Rademakers, Leonard M ^a   Jansen, Tim S ^a   Verheule, Sander ^a   Van Der Veen, Frederik H ^a   Maessen, Jos G ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Departments of Pharmacology   (Netherlands)

Author keywords

Amiodarone; Arrhythmia; Atrial; Pericardium; Sotalol

Indexed keywords

AMIODARONE; SOTALOL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFECT; ELECTROPHYSIOLOGY; EPICARDIUM; GOAT; INTRAPERICARDIAL DELIVERY; NONHUMAN; PERICARDIUM; PRIORITY JOURNAL; SINUS RHYTHM; STIMULATION;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FUNCTION, RIGHT; DRUG DELIVERY SYSTEMS; ELECTROPHYSIOLOGICAL PROCESSES; ENDOCARDIUM; GOATS; PERICARDIUM; SOTALOL; TISSUE DISTRIBUTION; VENTRICULAR FUNCTION, RIGHT;

EID: 74949134224     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181bad042     Document Type: Article

References (38)

1. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-1872.
2. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;4:CD005049.
3. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol. 2008;127:299-306.
4. Verrier RL, Waxman S, Lovett EG, et al. Transatrial access to the normal pericardial space: a novel approach for diagnostic sampling, pericardiocentesis, and therapeutic interventions. Circulation. 1998;98:2331-2333.
5. Maisch B, Ristic AD, Rupp H, et al. Pericardial access using the PerDUCER and flexible percutaneous pericardioscopy. Am J Cardiol. 2001;88:1323-1326.
6. D'Avila A, Scanavacca M, Sosa E, et al. Pericardial anatomy for the interventional electrophysiologist. J Cardiovasc Electrophysiol. 2003;14: 422-430.
7. Bartoli CR, Akiyama I, Godleski JJ, et al. Long-term pericardial catheterization is associated with minimum foreign-body response. Catheter Cardiovasc Interv. 2007;70:221-227.
8. Ota T, Patronik NA, Schwartzman D, et al. Minimally invasive epicardial injections using a novel semiautonomous robotic device. Circulation. 2008;118(Suppl 14):S115-S120.
9. Avitall B, Hare J, Zander G, et al. Iontophoretic transmyocardial drug delivery. A novel approach to antiarrhythmic drug therapy. Circulation. 1992;85:1582-1593.
10. LabhasetwarV, UnderwoodT, Gallagher M, et al. Sotalol controlled-release systems for arrhythmias: in vitro characterization, in vivo drug disposition, and electrophysiologic effects. J Pharm Sci. 1994;83:156-164.
11. Labhasetwar V, Strickberger SA, Underwood T, et al. Prevention of acute inducible atrial flutter in dogs by using an ibutilide-polymer-coated pacing electrode. J Cardiovasc Pharmacol. 1998;31:449-455.
12. Ayers GM, Rho TH, Ben-David J, et al. Amiodarone instilled into the canine pericardial sac migrates transmurally to produce electrophysiologic effects and suppress atrial fibrillation. J Cardiovasc Electrophysiol. 1996; 7:713-721.
13. Darsinos JT, Karli JN, Samouilidou EC, et al. Distribution of amiodarone in heart tissues following IPC administration. Int J Clin Pharmacol Ther. 1999;37:301-306.
14. Ujhelyi MR, Hadsall KZ, Euler DE, et al. Intrapericardial therapeutics: a pharmacodynamic and pharmacokinetic comparison between pericardial and intravenous procainamide delivery. J Cardiovasc Electrophysiol. 2002;13:605-611.
15. Vereckei A, Gorski JC, Ujhelyi M, et al. Intrapericardial ibutilide administration fails to terminate pacing-induced sustained atrial fibrillation in dogs. Cardiovasc Drugs Ther. 2004;18:269-277.
16. Van Brakel TJ, Hermans JJ, Accord RE, et al. Effects of intrapericardial sotalol and flecainide on transmural atrial electrophysiology and atrial fibrillation. J Cardiovasc Electrophysiol. 2009;20:207-215.
17. Hohnloser SH, Meinertz T, Dammbacher T, et al. Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study. Am Heart J. 1991;121:89-95.
18. Watt AH, Hutchings A, Stephens MR, et al. Plasma amiodarone concentrations during intravenous infusion. Br J Clin Pharmacol. 1986; 21:525-528.
19. Dorian P, Newman D, Sheahan R, et al. d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy. J Cardiovasc Electrophysiol. 1996;7:952-961.
20. Van Brakel TJ, Hermans JJ, Janssen BJ, et al. Intrapericardial delivery enhances cardiac effects of sotalol and atenolol. J Cardiovasc Pharmacol. 2004;44:50-56.
21. Bolderman RW, Hermans JJ, Maessen JG. Determination of the class III antiarrhythmic drugs dronedarone and amiodarone, and their principal metabolites in plasma and myocardium by high-performance liquid chromatography and UV-detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1727-1731.
22. Darsinos JT, Samouilidou EC, Krumholz B, et al. Distribution of lidocaine and digoxin in heart tissues and aorta following intrapericardial administration. Int J Clin Pharmacol Ther Toxicol. 1993;31:611-615.
23. Takada M, Dohi S, Akamatsu S, et al. Effects of pericardial lidocaine on hemodynamic parameters and responses in dogs anesthetized with midazolam and fentanyl. J Cardiothorac Vasc Anesth. 2007;21:393-399.
24. Kolettis TM, Kazakos N, Katsouras CS, et al. Intrapericardial drug delivery: pharmacologic properties and long-term safety in swine. Int J Cardiol. 2005;99:415-421.
25. Fei L, Baron AD, Henry DP, et al. Intrapericardial delivery of L-arginine reduces the increased severity of ventricular arrhythmias during sympathetic stimulation in dogs with acute coronary occlusion: nitric oxide modulates sympathetic effects on ventricular electrophysiological properties. Circulation. 1997;96:4044-4049.
26. Moreno R, Waxman S, Rowe K, et al. Intrapericardial beta-adrenergic blockade with esmolol exerts a potent antitachycardic effect without depressing contractility. J Cardiovasc Pharmacol. 2000;36:722-727.
27. Kumar K, Nguyen K, Waxman S, et al. Potent antifibrillatory effects of intrapericardial nitroglycerin in the ischemic porcine heart. J Am Coll Cardiol. 2003;41:1831-1837.
28. Xiao YF, Sigg DC, Ujhelyi MR, et al. Pericardial delivery of omega-3 fatty acid: a novel approach to reducing myocardial infarct sizes and arrhythmias. Am J Physiol Heart Circ Physiol. 2008;294:H2212-H2218.
29. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res. 1997;35:13-29.
30. Feng J, Yue L, Wang Z, et al. Ionic mechanisms of regional action potential heterogeneity in the canine right atrium. Circ Res. 1998;83:541-551.
31. Anyukhovsky EP, Rosenshtraukh LV. Electrophysiological responses of canine atrial endocardium and epicardium to acetylcholine and 4-aminopyridine. Cardiovasc Res. 1999;43:364-370.
32. Burashnikov A, Mannava S, Antzelevitch C. Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. Am J Physiol Heart Circ Physiol. 2004;286:H2393-H2400.
33. Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. Am J Physiol Heart Circ Physiol. 2007;293:H2024-H2038.
34. Holt DW, Tucker GT, Jackson PR, et al. Amiodarone pharmacokinetics. Am Heart J. 1983;106:840-847.
35. Hermans JJ, Van Essen H, Struijker-Boudier HA, et al. Pharmacokinetic advantage of intrapericardially applied substances in the rat. J Pharmacol Exp Ther. 2002;301:672-678.
36. Gupta P, Patel C, Patel H, et al. T(p-e)/QT ratio as an index of arrhythmogenesis. J Electrocardiol. 2008;41:567-574.
37. Tse HF, Lau CP. Electrophysiologic actions of DL-sotalol in patients with persistent atrial fibrillation. J Am Coll Cardiol. 2002;40:2150-2155.
38. Munoz A, Karila P, Gallay P, et al. A randomized hemodynamic comparison of intravenous amiodarone with and without Tween 80. Eur Heart J. 1988;9:142-148.